The Company projects Trudhesa will deliver prescriptions within the range of 80,000 – 110,000 TRx for full year 2023.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMPL:
- Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
- Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
- Impel Pharmaceuticals announces strategic reprioritization, departure of CMO
- Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity